Evaluation of the potential interactions between nanoparticles and biomolecules at the molecular level.

Assessment of potential cytotoxicity, immunogenicity, and unintended molecular effects [37].

Characterization of nanoparticle behavior in biological environments to ensure molecular compatibility.

Developing international standards for the evaluation and approval of nanomedicine products.

Establishing consistent guidelines for molecular safety assessment, efficacy evaluation, and quality control.

Collaboration between regulatory agencies to streamline approval processes for cross-border nanomedicine products.

Incorporating molecular safety assessments into the early stages of nanomedicine development.

Encouraging industry collaboration to share molecular safety data and foster responsible innovation.

Designing regulatory frameworks that adapt to the rapidly evolving nature of nanomedicine innovations.

Lack of standardized methods for evaluating molecular interactions and safety at the nanoscale.

Balancing the need for patient access to innovative nanomedicine products with robust safety assessments.

Addressing the unique challenges posed by multifunctional nanoparticles and novel molecular designs.

Ensuring that regulatory agencies have the expertise and capacity to evaluate nanomedicine products effectively.